Across TCGA pan-cancer cohorts, IGLC3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGLC3 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher IGLC3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLC3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KICH, DLBC, and SKCM are the cancer types where IGLC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
DLBC	DFS	Median	All	0.416	0.827	.047	2	view →
SKCM	DFS	Median	All	1.000	0.198	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGLC3 tumor-vs-normal RNA expression · all IGLC3 data types